In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug

• Main Authors: Isabel Gonzalez-Alvarez (Author), Alejandro Ruiz-Picazo (Author), Ruben Selles-Talavera (Author), Andres Figueroa-Campos (Author), Virginia Merino (Author), Marival Bermejo (Author), Marta Gonzalez-Alvarez (Author)
• Format: Book
• Published: MDPI AG, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The purpose of this study was to predict the in vivo bioequivalence (BE) outcome of valsartan (VALS, BCS class IV) from three oral-fixed combination products with hydrochlorothiazide (HCTZ, BCS class III) (<i>Co-Diovan^® Forte</i> as reference and two generic formul...